FLAREX SUMMARY
Flarex®
(fluorometholone acetate
ophthalmic suspension)
Sterile
FLAREX® (fluorometholone acetate) is a corticosteroid prepared as a sterile topical ophthalmic suspension.
FLAREX Ophthalmic Suspension is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.
|
NEWS HIGHLIGHTSMedia Articles Related to Flarex (Fluorometholone Ophthalmic)
Bacterial Conjunctivitis Drug Besivance Approved
Source: MedicineNet Pink Eye Specialty [2009.06.01]
Title: Bacterial Conjunctivitis Drug Besivance Approved
Category: Health News
Created: 6/1/2009
Last Editorial Review: 6/1/2009
Pink Eye Pictures Slideshow: Pink Eye (Conjunctivitis)
Source: MedicineNet Eye Allergy Specialty [2008.06.27]
Title: Pink Eye Pictures Slideshow: Pink Eye (Conjunctivitis)
Category: Slideshows
Created: 6/26/2008
Last Editorial Review: 6/27/2008
Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint In A Study Of Adult Subjects With A History Of Grass Pollen Allergies
Source: Allergy News From Medical News Today [2009.11.03]
Schering-Plough Corporation (NYSE: SGP) announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma.
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data At The American College Of Clinical Pharmacy (ACCP) 2009 Annual Meeting
Source: Allergy News From Medical News Today [2009.10.22]
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.
Published Studies Related to Flarex (Fluorometholone Ophthalmic)
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2009.08]
PURPOSE: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... CONCLUSIONS: In patients with SAC, olopatadine, ketotifen, epinastine and emedastine are more efficacious than fluorometholone acetate in preventing itching and redness. All the antiallergic agents gave similar results in terms of reducing tearing, chemosis and eyelid swelling. Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]
AIMS: Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%... CONCLUSIONS: Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG.
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Purpose: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Preclinical investigation of fluorometholone acetate as a potential new adjuvant during vitreous surgery. [2007.07]
OBJECTIVE: To examine the effects of intravitreal fluorometholone acetate (FMT) on the morphology and function of the retina and to investigate its possible use for vitreous surgery... CONCLUSION: FMT appears to be a potentially useful tool in assisting vitreous surgery including safe ILM peeling.
Clinical Trials Related to Flarex (Fluorometholone Ophthalmic)
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel [Recruiting]
|
